| LAK细胞混悬液局部注射治疗脑胶质瘤初步研究 |
| |
| 引用本文： | 康德智,陈锦峰,张国安,吴喜跃,林章雅,刘小朋,陈紫榕. LAK细胞混悬液局部注射治疗脑胶质瘤初步研究[J]. 福建医科大学学报, 1993, 0(4) |
| |
| 作者姓名： | 康德智 陈锦峰 张国安 吴喜跃 林章雅 刘小朋 陈紫榕 |
| |
| 作者单位： | 福建医学院附属第一医院神经外科，福建医学院附属第一医院神经外科，空军福州医院临床免疫研究室，福建医学院附属第一医院神经外科，福建医学院附属第一医院神经外科，空军福州医院临床免疫研究室，空军福州医院临床免疫研究室 |
| |
| 摘 要： | 用LAK细胞与白细胞介素2(γIL-2)及胸腺因子D(TFD)混合,于术中、术后注入瘤周和瘤腔,治疗7例脑胶质瘤患者,未见明显的毒性反应。1例CT显示术中残留的肿瘤消失;1例治疗部位未见肿瘤复发,而对照部位复发。该疗法用于临床是安全和具有一定疗效的。
|
| 关 键 词： | 脑肿瘤 免疫治疗 淋巴因子激活的杀伤细胞 白细胞介素2 胸腺因子D |
Preliminary Clinical Study of Intralesional Infusion of Lymphokine--activated Killer Cells suspended Fluid for the Treatment of Brain Glioma |
| |
| Kang Dezhi,Chen Jinfeng,Zhang Guoan. Preliminary Clinical Study of Intralesional Infusion of Lymphokine--activated Killer Cells suspended Fluid for the Treatment of Brain Glioma[J]. Journal of Fujian Medical University, 1993, 0(4) |
| |
| Authors: | Kang Dezhi Chen Jinfeng Zhang Guoan |
| |
| Affiliation: | Kang Dezhi,Chen Jinfeng,Zhang Guoan Department of Neurosurgery,First Affiliated Hospital of Fujian Medical College,Fuzhou |
| |
| Abstract: | Autologous or heterologous lymphokine-activated killer (LAK) cells initiated by recombinant inter- leukin-2 (rIL-2) and thymic factor D(TFD) were suspended in saline, rIL-2 and TFD, then were direct- ly injected into the brain tissue surrounding the tumor cavity left following tumor removal during cran- iotomy and infused into intracavity after the operation. Seven patients with glioma were treated. There have been no signs of systemic or neurotoxicity following treatment. The residue disappeared on comput- ed tomographic scan. Another showed no tumor recurrence at the site of treatment,but the controlled site did. We discussed the predominance and feasibility as well as the prevention and treatment of the side effects of intralesional infusion of LAK cells plus rIL-2 and TFD. The results demonstrated that the im- munotherapeutic regimen we have described is safe,feasible and effective for the treatment of patients with glioma. |
| |
| Keywords: | cerebral tumor immunotherapy LAK interleukin--2 thymic factor D |
| 本文献已被 CNKI 等数据库收录！ |
